Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bristol-Myers Squibb
(NY:
BMY
)
41.24
-0.30 (-0.72%)
Official Closing Price
Updated: 7:00 PM EDT, May 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Bristol-Myers Squibb
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
42
43
Next >
Why ParaZero Technologies Shares Are Trading Higher By Over 100%? Here Are Other Stocks Moving In Monday's Mid-Day Session
October 09, 2023
Gainers ParaZero Technologies Ltd. (NASDAQ: PRZO) shares jumped 106% to $2.3901 after the company announced an Australian regulator approved first commercial drone flights in populated areas and near...
Via
Benzinga
Why Shares of Tango Therapeutics Are Dropping Monday
October 09, 2023
Another company's buyout helped drive up the price last week. This week, investors started out by selling the stock.
Via
The Motley Fool
Mirati Therapeutics Snags $5.8 Billion Takeover Deal, But Shares Fall On Lowball Bid
October 09, 2023
Bristol Myers Squibb hopes to buy Mirati Therapeutics for up to $5.8 billion.
Via
Investor's Business Daily
Bristol-Myers Squibb Unusual Options Activity For October 06
October 06, 2023
Via
Benzinga
Bristol-Myers Squibb Unusual Options Activity For September 27
September 27, 2023
Via
Benzinga
Looking Into Bristol-Myers Squibb's Recent Short Interest
September 18, 2023
Via
Benzinga
Bristol Myers Squibb Strengthens Oncology Portfolio With Mirati Therapeutics' $5B Deal
October 09, 2023
Bristol Myers Squibb & Co (NYSE: BMY) has agreed to acquire Mirati Therapeutics Inc (NASDAQ: MRTX) for $58.00 per share in cash, for a total
Via
Benzinga
S&P 500, Nasdaq Set For Bleak Start To Week As Middle East Tensions Dampen Risk-On Mood: Earnings, Inflation Data In Focus
October 09, 2023
Trading in stock futures suggests a lower open on Monday as traders digest the ramification of the conflict in the Middle East.
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Tesla, Mirati Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
October 09, 2023
U.S. stock futures traded lower this morning on Monday. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
2 Growth Stocks That Could Rocket Higher Before the End of 2023
October 08, 2023
Potential approvals of new medicines expected soon could push these stocks through the roof.
Via
The Motley Fool
2 Undervalued Dividend Stocks to Buy Now
September 13, 2023
These two pharma titans are proven income vehicles.
Via
The Motley Fool
Thinking Of Buying Alexandria Real Estate Equities? Here Are The Properties And Tenants You'd Add To Your Portfolio
October 05, 2023
Via
Benzinga
Current Analysis: Bristol-Myers Squibb
October 04, 2023
Over the past year, Bristol’s share price dropped about 20.3% from $71.21 to $56.73 as of Wednesday’s market close.
Via
Talk Markets
Drugmakers Agree To Participate For Medicare Drug Price Negotiation With Biden Administration
October 03, 2023
All ten manufacturers of the first drugs selected for Medicare price negotiations will be participating, the White House said, even though many of them are suing the administration
Via
Benzinga
Cancer Drug Approval? 3 Biotech Stocks on the Brink of Breakthroughs
October 02, 2023
CAR T therapies have major advantages over traditional cancer drugs. Here are three of the best cancer drug stocks set to benefit from CAR T.
Via
InvestorPlace
Q4 Stock Predictions: 3 Pharma Stocks Ready to Roar Into 2024
October 02, 2023
The stars are aligning for these pharmaceutical giants, making their stocks look ready to run higher in next year.
Via
InvestorPlace
Medicare Drug Price Negotiation - What Court's Decision Means for Americans
October 02, 2023
A U.S. District Judge has upheld a pivotal initiative of President Joe Biden, giving the green light for Medicare to commence negotiations on prescription drug prices.
Via
Benzinga
Pharma Giants Shift Stance, Embrace Medicare Negotiations Amid Rising Drug Costs
September 28, 2023
AstraZeneca Plc (NASDAQ: AZN), Bristol Myers Squibb & Co (NYSE: BMY), and Boehringer Ingelheim are willing to participate in the initial round of Medicare drug price negotiation
Via
Benzinga
3 Dividend Stocks to Buy and Hold Until Retirement
September 28, 2023
Together, these stocks can also help diversify your portfolio by giving you exposure to different industries.
Via
The Motley Fool
3 Artificial Intelligence (AI) Stocks That Could Soar More Than Nvidia, According to Wall Street
September 25, 2023
None of these stocks have outperformed Nvidia so far this year. But the next 12 months could be a different story.
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Beware! 3 Healthcare Stocks Waving Massive Red Flags Right Now.
September 24, 2023
These three healthcare stocks to sell are waving red flags at investors who should pay attention or suffer the consequences.
Via
InvestorPlace
Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement
September 23, 2023
Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. The company will make...
Via
Talk Markets
Bristol Myers' Lead Cancer Drug Opdivo Regime Meets Primary Goal In Phase 3 Lung Cancer Study
September 22, 2023
Bristol Myers Squibb & Co (NYSE: BMY) announced interim data from Phase 3 CheckMate -77T trial evaluating the perioperative regimen of neoadjuvant (before surgery) Opdivo (nivolumab) with chemotherapy...
Via
Benzinga
Anemia Advantage For GSK's Blood Cancer Therapy Could Influence Market Share Despite Incyte's Jakafi Comparison
September 18, 2023
Friday, the FDA approved GSK plc's (NYSE: GSK) Ojjaara (momelotinib) for intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythemia vera and...
Via
Benzinga
Exposures
Product Safety
10 Health Care Stocks Whale Activity In Today's Session
September 15, 2023
Via
Benzinga
The 3 Most Undervalued Pharma Stocks to Buy in September 2023
September 14, 2023
Investing in pharmaceutical industry always carries risk, but several pharma stocks have an attractive risk/reward valuation right now.
Via
InvestorPlace
Bristol-Myers Squibb Plans To Double Clinical Pipeline Platforms To Support Long-Term Sustainable Growth
September 14, 2023
Bristol-Myers Squibb & Co (NYSE: BMY) announced its ambitious plan to double the number of treatments undergoing clinical trials in the next 18 months, focusing primarily on targeted protein
Via
Benzinga
The Next Walgreens CEO? My Top 3 Picks to Replace Roz Brewer.
September 13, 2023
Roz Brewer stepped down from leading Walgreens, and the next CEO is a tough choice. These three make the cut.
Via
InvestorPlace
Recent Pullback Buying Opportunity For Blood Cancer Firm Geron: Goldman Sachs
September 12, 2023
Goldman Sachs has upgraded Geron Corporation (NASDAQ: GERN) to Buy from Neutral, with a p
Via
Benzinga
Bristol Myers Squibb's Opdivo Plus Yervoy Combo Shows Durable, Long-Term Survival In Lung Cancer Patients
September 11, 2023
Bristol Myers Squibb & Co (NYSE: BMY) announced six-year results from Part 1 of the Phase 3 CheckMate -227 trial, which continues to demonstrate long-term, durable survival benefits of Opdivo...
Via
Benzinga
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
42
43
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.